Best Oncology Companies in Cambridge, United States

Developer of messenger ribonucleic acid therapies for immune cell programming. These therapies utilize lipid nanoparticle delivery systems to modify immune cells directly within the body. The technology targets specific cell types to address conditions related to oncology and autoimmunity. The approach focuses on the expression of chimeric antigen receptors to facilitate immune responses against disease targets.

Funding rounds

• May 2026Series B$122M

Founders & team

Daniel GettsCo-Founder & CEO

Investors

Newpath Partners, Hatteras Venture Partners, Arch Venture Partners, Alexandria Venture Investments

Developer of peptide therapeutics for the treatment of severe diseases. It offers a proprietary AI- and physics-based computational methods as discovery platform . It offers FOG-001 an inhibitor of β-catenin:TCF for colorectal cancers.

Funding rounds

• Jan 2026Series F$305M

Founders & team

Mathai MammenCEO

Investors

RA Capital Management, Fidelity Investments, Janus Henderson Investors, Frazier Life Sciences, Soleus Capital, Arch Venture Partners

Tech stack

Apple Icloud MailCloudflareCloudflare Bot ManagementDocusignDraftpress HfcmFont Awesome

Developer of allosteric therapeutics for precision oncology and rare diseases. The company integrated with proprietary drug discovery platform that enables to unlock novel allosteric binding pockets and rapidly advance structural insights into small molecule therapeutics designt to unlock cryptic allosteric sites across a broad range of target classes.

Funding rounds

• Mar 2026Series B$40M
• Dec 2025Series B$120M
• Dec 2023Series A$40M
• Aug 2021Series A$60M

Founders & team

Ralph DeBerardinisCo-FounderJared RutterCo-FounderBryan StuartCEO

Investors

The Column Group, Lux Capital, Nextech Invest, Regeneron Ventures, RA Capital Management

Developer of antibody therapies for cancer treatment. The company is advancing the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).

Funding rounds

• Mar 2026Series B$77M
• Sep 2025Series A$30.2M
• Jul 2023Series A$80M

Founders & team

Geraldine PaulusCo-FounderBriggs MorrisonCEO

Investors

Pfizer, Polaris Partners, BVF Partners, Mirae Asset Venture Investments, Mirae Asset, Lilly

Developer of mRNA-based therapeutics for a wide range of diseases. The company produces human proteins, antibodies, or vaccines inside patient cells, which are in turn active intracellularly or secreted. The company is also developing vaccines in different disease areas such as infectious diseases, cancer, rare diseases, and COVID-19.

Funding rounds

• Jan 2025Grant (prize money)$590M
• Jul 2024Grant (prize money)$176M
• Oct 2020Grant (prize money)$56M
• May 2020Post IPO—

Founders & team

Robert LangerCo-FounderKenneth ChienCo-FounderTimothy SpringerCo-Founder

Investors

ADIA, BB Biotech, Julius Baer, Sequoia Capital, Fidelity Investments, Viking Global Investors

Tech stack

AccessibeAmazon CloudfrontAmazon SesAmazon Web ServicesApolloApple Icloud Mail

Precision immunotherapies to transform patients' lives by selectively modulating the immune system. It is a biotechnology company engineering biologics designed to selectively engage and modulate targeted T cells. The company focuses on autoimmune diseases and cancer, aiming to restore immune balance. Their proprietary Immuno-STAT platform enhances a patient’s immune system to potentially restore health. They are developing a novel class of therapeutic biologics. The company's approach involves precision medicine, clinical development, and translational research. They are working towards establishing a new standard of care for diseases that cause human suffering and mortality. They are mobilizing the patient’s immune system to treat serious diseases.

Tango Therapeutics is a biotech company developing novel drugs for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening to identify targets for specific subgroups of cancer patients. The company is discovering novel targets using synthetic lethality, where the cancer-causing alteration in a tumour suppressor gene creates a vulnerability that leads to the destruction of the tumour cell.

Funding rounds

• Oct 2025Post IPO$15M
• Aug 2023Post IPO$80M
• Aug 2020Series B$50M
• Apr 2020Series B$60M

Founders & team

Barbara Weber MdPresident and CEO

Investors

Casdin Capital, Boxer Capital, Third Rock Ventures, Gilead, Tavistock Group, Roche

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

Developer of immunotherapeutics for immunological and cancer diseases. It offers anti-inflammation immunotherapies such as anti-TNF antibodies and JAK inhibitors for inflammatory diseases and cancer. It has a computational drug discovery platform.

Funding rounds

• Jun 2025Series D$214M
• Oct 2023Series C$117.2M
• Oct 2022Series B$168M
• Dec 2021Series A$218M

Founders & team

Paul-Albert KönigCo-Founder and Sr. Director BiologyCharlie KoniverCo-FounderGary GlickCo-Founder & CEO

Investors

General Catalyst, Alexandria, Walleye, Catalio Capital Management, GreatPoint Ventures, SVB Securities

Tech stack

Apple Icloud MailCdnjsCloudflareCloudflare Bot ManagementCookieyesCore-Js

Developer of novel vaccine formulations using a silk stabilization platform. Technology includes extracting fibroin from silk in which biological compounds are encapsulated to provide heat stability. It is also developing product formats that enable novel routes of administration like microneedles for transdermal applications. It has developed MIMIX therapies that help in treating cancers such as skin cancers, breast cancer, and infectious diseases.

Funding rounds

• Aug 2025Series D$7.9M
• Feb 2025Series D$9M
• Sep 2024Grant (prize money)$335.4K
• May 2024Series D$10.8M

Founders & team

Livio ValentiCo-FounderKathryn KosudaCo-Founder

Investors

Norwich Ventures, Engine, Mission BioCapital, Gates, RA Capital Management, Ulu Ventures

Tech stack

Cart FunctionalitySquarespace CommerceSquarespaceYoutubeStimulusPriority Hints

Developer of disruptive therapies for oncology and infectious diseases. It provides TAER-TAB technology which is a bispecific antibody (bsAb) platform that targets cancer cells. It also provides ViTRAP technology which is a broad-spectrum antiviral therapeutics platform.

Funding rounds

• Nov 2025Series B$47M
• Jul 2024Series A$17M
• Jun 2022Series A$23.5M

Founders & team

Hojuhn SongCo-Founder & CEO

Investors

Stick Investment, DSC Investment, Samho Green Investment, Atinum Investment, Schmidt, S&S Investment

Developer of therapies for treating cancer. The lead candidate of the company acts on HER-2 a member of the human epidermal growth factor receptor such as HER/EGFR/ERB which is used to treat Osteosarcoma. Also, developing folate receptor-targeted TDC for ovarian, pancreatic, lung, and others.

Funding rounds

• Mar 2026Post IPO$2M
• Jan 2026Post IPO$3.5M
• Sep 2025Post IPO$3.8M
• Jun 2025Post IPO$4.2M

Founders & team

Paul RomnessCEO

Investors

K20 Fund

Tech stack

AosApache Http ServerBootstrapCdnjsCivicthemeCloudflare

Provider of an AI-enabled bioinformatics platform for clinical solutions. It provides advanced data analysis services using state-of-the-art technologies including proprietary algorithms. Some of the datasets it uses to analyze are gene expression (microarray), single-nucleotide polymorphism (SNP), proteomic, clinical metadata, and next-generation sequencing (NGS) including RNAseq, exome sequencing, and whole-genome sequencing. It captures difficult-to-find signals, generates biological hypotheses, and designs follow-up studies, contributing to the development of medicines for patients with cancer, autoimmune disease, neurodegeneration, and other serious diseases.